RetroSense Therapeutics Signs License Agreement With Massachusetts General Hospital, Expanding Its Optogenetics Intellectual Property Portfolio

ANN ARBOR, Mich.--(BUSINESS WIRE)--RetroSense Therapeutics, a privately-held biopharmaceutical company, today announced the signing of a license agreement for exclusive, worldwide rights to Massachusetts General Hospital’s patent application entitled "Method for Augmenting Vision in Persons Suffering from Photoreceptor Cell Degeneration". Licensing provides RetroSense with worldwide access to key intellectual property which reinforces the Company’s dominant position in optogenetics for vision restoration.

Help employers find you! Check out all the jobs and post your resume.